HMP Global October 7, 2022

Health care decision makers are reviewing digital therapeutics with an emphasis on mobile apps, but prior authorization coverage is being provided to a limited number, reported study authors at AMCP Nexus 2022.

To gather insights on digital therapeutics product evaluations, evidence exchange approaches, and formulary coverage and utilization management, researchers conducted a double-blind web-based survey between April 2022 and May 2022, which was completed by 50 respondents.

Per the results, mobile apps (60%) were the most often reviewed digital therapeutics followed by drug-delivery device combinations (44%), and medication adherence platforms (38%) in the past 12 to 18 months.

Researchers reported that coverage benefit was most commonly dependent on the specific product (42%), but mobile apps (30%) and drug delivery device...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Apps, Digital Health, Insurance, Payer, Survey / Study, Technology, Trends
How Are Telehealth CEOs Reacting to Congress’ Latest Spending Legislation?
Digital mental health programs are inexpensive and innovative. But do they work?
DIY Healthcare Can Help Counter the Physician Shortage
Search Funds growing interest in Healthcare Technology
Canada's Virtual Health Hub will bring needed access to care

Share This Article